您的购物车当前为空
CTAP TFA 是一种强效、高选择性的、可透过血脑屏障的阿片受体 (μopioid receptor) 拮抗剂,IC50为 3.5 nM。CTAP TFA 对δ opioid 受体 (IC50=4500 nM) 和生长抑素受体 (somatostatin receptors) 具有超过 1200 倍的选择性。CTAP TFA 可用于L -多巴胺 诱导的运动障碍 (LID) 和阿片类活性分子过量或成瘾的研究。
CTAP TFA 是一种强效、高选择性的、可透过血脑屏障的阿片受体 (μopioid receptor) 拮抗剂,IC50为 3.5 nM。CTAP TFA 对δ opioid 受体 (IC50=4500 nM) 和生长抑素受体 (somatostatin receptors) 具有超过 1200 倍的选择性。CTAP TFA 可用于L -多巴胺 诱导的运动障碍 (LID) 和阿片类活性分子过量或成瘾的研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
CTAP TFA 相关产品
| 产品描述 | CTAP TFA, a potent and highly selective μ opioid receptor antagonist that effectively crosses the blood-brain barrier, exhibits a significant inhibition concentration (IC50) of 3.5 nM. It demonstrates extraordinary selectivity, being over 1200-fold more specific to μ opioid receptors than to δ opioid (IC50 = 4500 nM) and somatostatin receptors. This compound is primarily leveraged for researching L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction [1] [2]. |
| 靶点活性 | δ Opioid Receptor/DOR:4500 nM, μ opioid receptor:3.5 nM |
| 分子量 | 1218.32 |
| 分子式 | C53H70F3N13O12S2 |
| Sequence | Phe-Cys-Tyr-Trp-Arg-Thr-Pen-Thr-NH2 (Disulfide bridge:Cys2-Pen7) |
| Sequence Short | FCYWRT{Pen}T-NH2 (Disulfide bridge:Cys2-Pen7) |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容